BigHat Biosciences, a biotech startup working on what it calls next-generation antibodies for use in new therapies, raised $19 million in its Series A funding round. With the new capital it will continue development of its artificial intelligence-assisted antibody design platform.
Next-generation antibody startup BigHat raises $19M
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.